Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Classical hematology 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 21Lymphoma, Mantle-Cell 10Lymphoma, Non-Hodgkin 7Lymphoma 6Waldenstrom Macroglobulinemia 4Recurrence 4Lymphoma, Follicular 4Lymphoma, B-Cell 4Bronchiolitis Obliterans Syndrome 3Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, B-Cell 2Hematologic Diseases 2Lymphoproliferative Disorders 1Lymphatic Diseases 1Leukemia, Lymphoid 1Leukemia 1Immunoproliferative Disorders 1Immune System Diseases 1Hepatitis B, Chronic 1Graft vs Host Disease 1Anemia 1

Interventions

Epoetin Alfa 27Darbepoetin alfa 13epoetin beta 3Erythropoietin 3telapristone acetate 2luspatercept 2ferric carboxymaltose 2Lenalidomide 2Ferric Oxide, Saccharated 2Cisplatin 2Blood Transfusion 211-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 2ibrutinib 1fludarabine phosphate 1fludarabine 1ferrous sulfate 1ferric gluconate 1ferric derisomaltose 1fanasil, pyrimethamine drug combination 1Taxes 1Sugars 1Sucrose 1Solutions 1Saline Solution 1Rituximab 1Radiotherapy 1Pharmacogenomic Testing 1Paclitaxel 1Iron-Dextran Complex 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Anemia × ibrutinib × Clear all
NCT02048813 2026-05-29

Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
529 enrolled 12 charts 1 FDA
Classical hematologyLymphoidOther hematologic neoplasm

Anemia, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡